Please assess the completion status of the following clinical trial:

Trial Title: BOTOX® Treatment in Pediatric Upper Limb Spasticity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Minimum weight of 10 kg/22 lb~* Upper limb spasticity due to cerebral palsy or stroke~Exclusion Criteria:~* Muscular dystrophy, myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or mitochondrial disease~* Uncontrolled epilepsy~* Botulinum Toxin therapy of any serotype for any condition within the last 6 months~* Previous surgical treatment of the study limb (except tendon lengthening), or planned surgery of the study limb during the study~* Previous casting of the study limb for spasticity within 6 months or with a dynamic splint within 3 months, or planned casting or dynamic splinting for spasticity of the study limb or affected lower limb during the study

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- BOTOX® 3 U/kg (Type: EXPERIMENTAL): Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 3 units (U) per kilogram (kg) of body weight (3 U/kg) into specified muscles of the upper limb on Day 1. Participants received weekly occupational therapy (OT).
- BOTOX® 6 U/kg (Type: EXPERIMENTAL): Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 6 U per kg of body weight (6 U/kg) into specified muscles of the upper limb on Day 1. Participants received weekly OT.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received intramuscular injections of normal saline (placebo) into specified muscles of the upper limb on Day 1. Participants received weekly OT.

Based on this trial design, predict the completion outcome and termination type (if applicable).